| 62.87 1.08 (1.75%) | 04-13 14:07 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 79.27  |
1-year : | 84.52 |
| Resists | First : | 67.87 |
Second : | 72.37 |
| Pivot price | 64.68 |
|||
| Supports | First : | 60.59 | Second : | 50.41 |
| MAs | MA(5) : | 62.06 |
MA(20) : | 66.09 |
| MA(100) : | 83.71 |
MA(250) : | 94.79 |
|
| MACD | MACD : | -3.3 |
Signal : | -3.3 |
| %K %D | K(14,3) : | 12.8 |
D(3) : | 11.2 |
| RSI | RSI(14): 34.4 |
|||
| 52-week | High : | 109.5 | Low : | 60.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BSX ] has closed above bottom band by 36.1%. Bollinger Bands are 14.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 61.84 - 62.28 | 62.28 - 62.62 |
| Low: | 60.02 - 60.48 | 60.48 - 60.85 |
| Close: | 61.18 - 61.9 | 61.9 - 62.46 |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Mon, 13 Apr 2026
Deadline Alert: Boston Scientific Corporation (BSX) - GlobeNewswire
Sun, 12 Apr 2026
Is Boston Scientific Corporation (BSX) a good stock to buy now? - MSN
Fri, 10 Apr 2026
BSX Forecast, Price Target & Analyst Ratings | BOSTON SCIENTIFIC CORP (NYSE:BSX) - ChartMill
Fri, 10 Apr 2026
BSX Price History for Boston Scientific Corp Stock - Barchart.com
Fri, 10 Apr 2026
Jefferies Reiterates a Buy Rating on Boston Scientific Corporation (BSX), Sets a $130 PT - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1,490 (M) |
| Shares Float | 1,480 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 95 (%) |
| Shares Short | 25,440 (K) |
| Shares Short P.Month | 26,640 (K) |
| EPS | 1.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.34 |
| Profit Margin | 14.4 % |
| Operating Margin | 19.6 % |
| Return on Assets (ttm) | 5.9 % |
| Return on Equity (ttm) | 12.4 % |
| Qtrly Rev. Growth | 15.8 % |
| Gross Profit (p.s.) | 9.26 |
| Sales Per Share | 13.46 |
| EBITDA (p.s.) | 3.58 |
| Qtrly Earnings Growth | 18.5 % |
| Operating Cash Flow | 4,530 (M) |
| Levered Free Cash Flow | 3,240 (M) |
| PE Ratio | 32.37 |
| PEG Ratio | 0 |
| Price to Book value | 3.84 |
| Price to Sales | 4.66 |
| Price to Cash Flow | 20.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|